Edition:
United States

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

5.62USD
10:36am EST
Change (% chg)

$-0.02 (-0.35%)
Prev Close
$5.64
Open
$5.65
Day's High
$5.65
Day's Low
$5.60
Volume
1,576
Avg. Vol
38,126
52-wk High
$7.53
52-wk Low
$1.52

Chart for

About

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management... (more)

Overall

Beta: 0.28
Market Cap(Mil.): $76.88
Shares Outstanding(Mil.): 13.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

Dec 13 2017

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-BioLife Solutions posts Q3 loss per share $0.03

* Biolife Solutions announces third quarter 2017 financial results

Nov 09 2017

BRIEF-Biolife Solutions to report Q3 results and provide business update on Nov 9

* Biolife Solutions to report third quarter 2017 financial results and provide business update on November 9, 2017 Source text for Eikon: Further company coverage:

Nov 02 2017

BRIEF-BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin

* BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin Source text for Eikon: Further company coverage:

Sep 19 2017

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

Jul 31 2017

BRIEF-Biolife Solutions modifies existing credit facility

* Biolife Solutions Inc - has reached an agreement with wavi holding to modify its existing credit facility effective June 30, 2017

Jul 05 2017

Competitors

Earnings vs. Estimates